Regulators Encourage Transition from Batch to Continuous Processing
This article was originally published in The Gold Sheet
Executive SummaryAs pharmaceutical manufacturers increasingly look to continuous processing technologies as a way of controlling costs and potentially increasing drug quality, regulators in the U.S. and the European Union are beginning to use more flexible, quality-by-design-like approaches in evaluating these systems.
You may also be interested in...
Ben Venue shuttered; Teva squeezed; Wockhardt troubled; McKinsey would cut inventories and shortages; FDA says why it won’t review some ANDAs – what are they saying about it at “The Gold Sheet” on LinkedIn? Join the discussions of these and other recent news developments at “The Gold Sheet” LinkedIn group.